Patent Grant
9080155
The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is 200187_414USPC_SEQUENCE_LISTING.txt. The text file is 26.8 KB, was created on Jun. 20, 2013, and is being submitted electronically via EFS-Web.
The present invention relates to a novel protein having O-acetylhomoserine sulfhydrylase activity, a mutant protein thereof, a polynucleotide encoding the same, a recombinant vector comprising the polynucleotide, a microorganism transformed with the recombinant vector, and a method for producing methionine or acetic acid using the protein.
L-methionine which is one of the essential amino acids in vivo is contained in most of proteins and is present in a free state in soy sauce which is one of seasoning. It is widely used as feed and food additives, and is also used as infusion solution for medical usage or raw material for synthesizing medicines. Methionine is an important amino acid involved in methyl transfer reaction in vivo. First, by reacting with ATP, methionine is converted to δ-adenosylmethionine, which then donates methyl group to various acceptors; and then it is converted to cysteine via homocysteine and cystathionine. A red bread mold synthesizes methionine from cysteine. A scent of fermented foods such as soy sauce or cheese is often due to aldehyde, alcohol, and/or ester derived from methionine.
Also, methionine acts as a precursor of the compounds such as choline, lecithin, and creatine, and is used as raw material for synthesizing cysteine and taurine, and serving as a sulfur donor. In addition, methionine is associated with the synthesis of various neurotransmitters in the brain. Methionine and/or S-adenosyl-L-methionine (SAM) inhibit accumulation of fat in liver and arteries in vivo, and take various roles such as alleviating depression, inflammation, liver disease, and muscle pain. Furthermore, methionine and/or S-adenosyl-L-methionine provide various functions such as inhibiting fat deposition in a liver, which promotes fat metabolism, and arteries, increasing bloodstream circulation in a brain, heart, and kidney, stimulating digestion, promoting detoxification and excretion of toxic substances, and promoting the excretion of heavy metals such as lead. It has been reported that daily intake of 800 to 1,600 mg of methionine exhibits superior antidepressant effect, improvement of liver function in patients with liver diseases, particularly liver diseases caused by alcohol, excellent anti-inflammatory effect in bone joint disease, and stimulation of joint recovery in the same. Also, as an essential nutrient for hair, methionine is known to provide nourishment to the brittle hair, preventing hair loss.
For a chemical synthesis of methionine, most commonly L-methionine is produced through hydrolysis of 5-(β-methylmercaptoethyl)-hydantoin. However, when methionine is produced by such chemical synthesis process, there is disadvantage of producing mixed forms of L-type and D-type. In this regard, there is a patent disclosing the technique that allows a selective production of L-methionine using a biological approach (WO2008/013432). This method, named simply as a two-step method, comprises a process of converting the L-methionine precursor by fermentation and a process of converting the L-methionine precursor to L-methionine by using enzymes. The type of L-methionine precursor preferably comprises O-acetylhomoserine and O-succinylhomoserine. Development of the two-step method resolves all the existing problems such as toxicity of a substrate specific to sulfide, feedback control in a strain by methionine and SAM, and decomposition of intermediate product specific to cystathionine gamma synthase, O-succinylhomoserine sulfhydrylase, and O-acetylhomoserine sulfhydrylase. Furthermore, this method, which produces only L-methionine selectively, is superior to the conventional chemical synthesis process that produces both of D-methionine and L-methionine simultaneously, and this method can additionally produce organic acid, more specifically, succinic acid and acetic acid, as by-product through the same reaction.
The enzymatic conversion process in the two-step method employs the enzymes having cystathionine gamma synthase activity, O-succinylhomoserine sulfhydrylase activity or O-acetylhomoserine sulfhydrylase activity, and produces L-methionine and organic acids through enzyme reaction of O-acetylhomoserine or O-succinylhomoserine, which is a precursor of L-methionine, with methyl mercaptan.
In the enzymatic conversion reaction for producing L-methionine from O-acetylhomoserine, which is a precursor of L-methionine, various microbial-derived O-acetylhomoserine sulfhydrylases may be used. However, in order to be used as industrial convertase, the enzyme needs to meet several requirements to maximize cost-effectiveness. Firstly, the enzyme should have the characteristics of high activity and high conversion rate, and the overexpression thereof should be possible in E. coli. In general, for the reactions that use a purified enzyme, the activity of enzyme, reaction rate, and high affinity to a substrate are essential. But, if enzyme homogenate is added directly into the reaction, the overexpression of enzyme per unit cell should be possible in addition to having a high activity, in order to proceed the reaction with a minimal amount of homogenate. Secondly, the enzyme needs to maintain a high reaction rate with O-acetylhomoserine at high concentration, and the inhibition of its activity should be low even with accumulation of final products L-methionine and acetic acid to high concentration. Lastly, the enzyme should have a thermal stability to maintain its activity during the 1- to 5-hour long reaction. Considering the above requirements, a previously disclosed O-acetylhomoserine sulfhydrylase derived from Hyphomonas neptunium is an excellent enzyme, however in order to maximize the commercial value of the two-step method for producing methionine, a search for the enzymes with enhancement of the three characteristics is necessary.
The present inventors have obtained O-acetylhomoserine sulfhydrylase genes from various microbial sources and finally selected O-acetylhomoserine sulfhydrylase gene from Rhodobacter sphaeroides through experiments. Then after using the enzyme in a conversion reaction, the inventors have found that O-acetylhomoserine sulfhydrylase from Rhodobacter sphaeroides is an economically viable convertase to be applied in the two-step method for producing methionine, and also confirmed that the economic viability of the convertase can be enhanced by improving the enzyme through introducing mutations, thereby completing the present invention.
One objective of the present invention is to provide a novel protein having O-acetylhomoserine sulfhydrylase activity.
Another objective of the present invention is to provide a polynucleotide encoding the novel protein.
Another objective of the present invention is to provide a mutant protein having enhanced O-acetylhomoserine sulfhydrylase activity.
Another objective of the present invention is to provide a polynucleotide encoding the mutant protein.
Another objective of the present invention is to provide a recombinant vector comprising the polynucleotide.
Another objective of the present invention is to provide a microorganism transformed with the recombinant vector.
Another objective of the present invention is to provide a method for producing methionine or acetic acid from the precursors O-acetylhomoserine and methyl mercaptan, using the protein, or microorganism producing the same.
The present invention provides a protein having the activity of O-acetylhomoserine sulfhydrylase derived from Rhodobacter sphaeroides, which is required for producing L-methionine and acetic acid from a substrate methyl mercaptan (CH3SH). If the protein is used, it has the advantage of producing L-methionine and acetic acid economically through having higher conversion rate and reduced reaction time compared to the existing methods that use a protein having the activity of O-acetylhomoserine sulfhydrylase from Hyphomonas neptunium. In addition, if the mutant protein with enhanced activity of O-acetylhomoserine sulfhydrylase of the present invention is used, this can minimize the amount of enzyme homogenate added, thereby easily producing L-methionine and acetic acid at high yield.
a and 2b show the HPLC results, demonstrating the production of methionine. First, 5 to 10% homogenate of microorganism (of a total reaction volume) comprising the protein was added to the fermentation broth of O-acetylhomoserine, and the reaction was initiated by adding 15% Na-methyl mercaptan at a pH of 6 to 8. After 2 hours, the fermentation broth was collected and the cells were removed therefrom to analyze methionine production.
As one aspect, the present invention provides a novel protein having O-acetylhomoserine sulfhydrylase activity.
In the present invention, the protein having O-acetylhomoserine sulfhydrylase activity refers to a novel protein capable of synthesizing L-methionine using O-acetylhomoserine, which is a precursor of L-methionine, and methyl mercaptan. The novel protein is preferably a protein having O-acetylhomoserine sulfhydrylase activity from Rhodobacter sphaeroides. For the purpose of the present invention, the novel protein includes any protein having O-acetylhomoserine sulfhydrylase activity without limitation, but it may preferably be the protein of SEQ ID No. 13.
As used herein, the term “O-acetylhomoserine” is a substance with a molecular weight of 161.16 and is the first specific intermediate in biosynthesis of methionine in microorganisms. In intestinal bacteria O-succinylhomoserine is used as an intermediate instead of O-acetylhomoserine, and in higher plants O-phosphohomoserine is used as an intermediate. O-acetylhomoserine is generated from L-homoserine and acetyl-CoA by homoserine acetyltransferase catalysis at the bifurcation with biosynthesis of threonine.
Patent Publication WO2008/013432 discloses a process of producing L-methionine using a two-step method, and in this process, O-succinylhomoserine and O-acetylhomoserine are the two types of O-acylhomoserine which is a precursor used for producing L-methionine.
As used herein, the term “precursor” refers to a substance produced at the preceding step of a final product in a metabolism or biosynthetic reaction. For the purpose of the present invention, the precursor refers to a metabolite produced by L-methionine precursor-producing strain as a part of the methionine-specific metabolic pathway, or derivatives thereof. Specifically, the L-methionine precursor of the present invention refers to O-succinylhomoserine or O-acetylhomoserine.
The enzymes capable of producing methionine from O-succinylhomoserine among the L-methionine precursors through enzyme conversion include cystathionine gamma synthase and O-succinylhomoserine sulfhydrylase. In general, the gene encoding cystathionine gamma synthase is commonly noted as metB, and the gene encoding O-succinylhomoserine sulfhydrylase is commonly noted as metZ. These enzymes have the following three activities.
L-cysteine+O-succinylhomoserine=>succinic acid+cystathionine
sulfide (HS−)+O-succinylhomoserine=>succinic acid+homocysteine
methyl mercaptan+O-succinylhomoserine=>succinic acid+L-methionine
O-acetylhomoserine sulfhydrylase is an enzyme capable of producing L-methionine by using O-acetylhomoserine which is another L-methionine precursor. In general, the gene encoding O-acetylhomoserine sulfhydrylase is commonly noted as metY. This enzyme has the following three activities.
L-cysteine+O-acetylhomoserine=>acetic acid+cystathionine
sulfide (HS−)+O-acetylhomoserine=>acetic acid+homocysteine
methyl mercaptan+O-acetylhomoserine=>acetic acid+L-methionine
Using O-acetylhomoserine which requires less carbon sources such as glucose and raw sugar for producing two L-methionine precursors is more cost-effective in L-methionine production. However, while MetZ enzyme which is O-succinylhomoserine sulfhydrylase does not get a feedback inhibition from its final product L-methionine, MetY enzyme which is O-acetylhomoserine sulfhydrylase is inhibited by its product L-methionine, and therefore MetY is hard to use in enzymatic reaction.
In one example of the present invention, through testing various metZ genes for their activities, the Rhodobacter sphaeroides-derived metZ gene having O-acetylhomoserine sulfhydrylase activity was identified although it was previously expected to be an O-succinylhomoserine sulfhydrylase. Furthermore, it was confirmed that Rhodobacter sphaeroides-derived metZ does not get a feed inhibition by L-methionine. The selected protein having O-acetylhomoserine sulfhydrylase activity may have an amino acid sequence of SEQ ID No. 13.
In one example of the present invention, substrate specificity, expression level of convertase, and activity of convertase were compared among the proteins having the activity of O-acetylhomoserine sulfhydrylase derived from Hyphomonas species and O-acetylhomoserine sulfhydrylase derived from Rhodobacter species. As a result, it was found that when L-methionine is produced by using a mutant protein of O-acetylhomoserine sulfhydrylase derived from Rhodobacter species, the mutant protein showed higher substrate specificity toward O-acetylhomoserine than O-succinylhomoserine (Table 1), and it also demonstrated an improved enzymatic activity during early phase of reaction, improved reaction rate and L-methionine conversion rate (Table 2). In addition, when the inhibition levels by final products were compared among the recombinant mutant proteins derived from the two strains, O-acetylhomoserine sulfhydrylase derived from Rhodobacter species maintained a high activity in L-methionine production even with feedback inhibition by the final product thereof (Table 3). Furthermore, when a thermal stability of the enzyme relative to reaction temperature was compared, the mutant protein of O-acetylhomoserine sulfhydrylase derived from Rhodobacter species showed a superior thermal stability compared to the mutant protein of O-acetylhomoserine sulfhydrylase derived from Hyphomonas species (Table 4).
Therefore, the protein having O-acetylhomoserine sulfhydrylase activity of the present invention satisfies all the requirements to be used as industrial convertase including high activity, high conversion rate, overexpression in E. coli, low inhibition of enzyme activity by final product and capability to maintain thermal stability at the time of accumulation of final product, and thus by using the enzyme of the present invention, L-methionine and acetic acid can be produced at high rate and high efficiency.
As another aspect, the present invention provides a mutant protein having enhanced O-acetylhomoserine sulfhydrylase activity than a wild type.
As used herein, the term “mutation” or “mutant protein” refers to a culture or individual demonstrating a single stable genetic or non-genetic phenotypic change. In the present invention, a mutant protein preferably refers to a protein which activity is increased compared to the wild type due to a mutation in one or more of the genes encoding O-acetylhomoserine sulfhydrylase derived from Rhodobacter sphaeroides. The sequence of the mutant protein may comprise the sequence of protein having a homology of at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% to the sequence of wild type. Preferably, the protein may be a mutant protein having an enhanced O-acetylhomoserine sulfhydrylase activity through a mutation wherein the 3rd amino acid from the N-terminal of the protein represented by the amino acid sequence of SEQ ID No. 13 is substituted with an amino acid other than isoleucine, the 65th amino acid from the same is substituted with an amino acid other than phenylalanine, and the 104th amino acid from the same is substituted with an amino acid other than valine, or a combination of one or more of the three types of amino acid mutations is made. More preferably, two or more and even more preferably, three types of mutations can be combined. Even more preferably, the protein may be a mutant protein wherein the 3rd amino acid from the N-terminal, isoleucine, is substituted with asparagine, and the 65th amino acid, phenylalanine, is substituted with tyrosine, and the 104th amino acid, valine, is substituted with alanine. The amino acid sequence of the mutant protein may preferably be a mutant protein having the amino acid sequence of SEQ ID No. 15, 16, 17, or 18.
Specifically, a mutant protein represented by the amino acid sequence of SEQ ID No. 15 is a variant form of the protein represented by the amino acid sequence of SEQ ID No. 13 wherein the 3rd amino acid from the N-terminal of the same, isoleucine, is substituted with asparagine.
The mutant protein represented by the amino acid sequence of SEQ ID No. 16 has a substitution of phenylalanine, which is the 65th amino acid from the N-terminal of the protein represented by the amino acid sequence of SEQ ID No. 13, by tyrosine.
The mutant protein represented by the amino acid sequence of SEQ ID No. 17 has a substitution of valine, which is the 104th amino acid from the N-terminal of the protein represented by the amino acid sequence of SEQ ID No. 13, by alanine.
In addition, the mutant protein represented by the amino acid sequence of SEQ ID No. 18 has a substitution of isoleucine, which is the 3rd amino acid from the N-terminal of the protein represented by the amino acid sequence of SEQ ID No. 13, by asparagine, a substitution of phenylalanine, the 65th amino acid, by tyrosine, and a substitution of valine, the 104th amino acid, by alanine.
In one example of the present invention, based on the above findings four mutant proteins such as I3N, F65Y, V104A and E182G with improved enzymatic activity of mutant protein of O-acetylhomoserine sulfhydrylase derived from Rhodobacter species were generated. Then, three valid mutant proteins such as I3N, F65Y, and V104A were selected by measuring the activity of the mutant proteins (Table 9). A vector comprising the combination of the three valid mutant proteins was prepared, and transfected into E. coli. After measuring the activity of each mutant protein, it was found that the mutant proteins had 1.75 times increased activity than that of wild type O-acetylhomoserine sulfhydrylase (Table 10).
As another aspect, the present invention provides a polynucleotide encoding a novel protein having O-acetylhomoserine sulfhydrylase activity or a mutant protein having enhanced O-acetylhomoserine sulfhydrylase activity than a wild type.
As used herein, the term “polynucleotide” refers to a polymer of nucleotides having nucleotide monomers linked in a long chain by covalent bonding, and generally it means a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) strand longer than a certain length. For the purpose of the present invention, the polynucleotide may be a polynucleotide fragment encoding the protein. This polynucleotide fragment comprises polynucleotide fragments having a homology of at least 80%, 90%, 95%, 96%, 97%, 98%, or 99% to the sequence of polynucleotide fragment having O-acetylhomoserine sulfhydrylase activity.
Preferably, the polynucleotide may be the polynucleotide represented by the nucleotide sequence of SEQ ID No. 14. The polynucleotide represented by the nucleotide sequence of SEQ ID No. 14 is the polynucleotide encoding the wild type protein having the amino acid sequence of SEQ ID No. 13.
In addition, the polynucleotide encoding the mutant protein may have the nucleotide sequence of SEQ ID No. 19, 20, 21 or 22. The polynucleotides having the nucleotide sequence of SEQ ID Nos. 19, 20, 21 and 22 are the polynucleotides encoding the proteins having the amino acid sequences of SEQ ID Nos. 15, 16, 17, and 18 respectively.
As used herein, the term “homology” refers to a percentage of identity between two polynucleotide moieties. Sequence correspondence from one moiety to another can be determined by the known technique in the art. For example, homology can be determined by aligning the sequence information of two polynucleotide molecules directly by using a computer program that is readily available and capable of aligning sequence information. In addition, homology can be determined by hybridizing the polynucleotides under the condition for forming a stable double-strand in the homologous regions and digesting the hybridized strand by a single-strand-specific nuclease to determine a size of digested fragment.
As used herein, the term “homologous” refers to the correlation between proteins where all grammatical forms and spelling variations include superfamily-derived proteins (e.g., immunoglobulin superfamily) and other species-derived homologous proteins (e.g., myosin light chain, etc.) having a ‘common evolutionary origin’. Such proteins (and coding genes thereof) have a sequence homology reflected by a high degree of sequence similarity. However, in a general use and in the present invention, when the term “homogeny” is modified by an adjective such as ‘very high’, it refers to a sequence similarity, but not a common evolutionary origin.
As used herein, the term “sequence similarity” refers to the degree of identity or homology among the nucleotide sequences or amino acid sequences of the proteins which may or may not share a common evolutionary origin. In one specific example, when a polypeptide match between two amino acid sequences is least 21% for a fixed length of amino acid sequence (preferably at least about 50% and most preferably about 75%, 90%, 95%, 96%, 97% or 99%), those two sequences are ‘substantially homologous’ or ‘substantially similar’. Substantially homologous sequences can be identified by comparing the sequences using standard software used in the data bank or, for example, by performing Southern hybridization experiment under the stringent conditions defined for a certain system. A defined condition suitable for hybridization is within the scope of conventional techniques in the art (for example, Sambrook et al., 1989, see infra).
As another aspect, the present invention provides a recombinant vector comprising a polynucleotide encoding the wild type O-acetylhomoserine sulfhydrylase or mutant protein thereof.
As used herein, the term “vector” refers to any carrier for cloning and/or transferring nucleotides to a host cell. A vector may be a replicon to allow for the replication of the fragments combined with other DNA fragments. “Replicon” refers to any genetic unit acting as a self-replicating unit for DNA replication in vivo, that is, replicable by the self-regulation (e.g., plasmid, phage, cosmid, chromosome, and virus). The vector may include viral and non-viral carrier for introducing nucleotides into a host cell in vitro, ex vivo or in vivo, and also may include a mini-spherical DNA. For example, the vector may be a plasmid without a bacterial DNA sequence. Removal of bacterial DNA sequences which are rich in CpG area has been conducted to reduce a silencing of the transgene expression and to promote more continuous expression from a plasmid DNA vector (Ehrhardt, A. et al. (2003) Hum Gene Ther 10: 215-25; Yet, N. S. (2002) Mol Ther 5: 731-38; Chen, Z. Y. et al. (2004) Gene Ther 11: 856-64). In addition, the vector may comprise a transposon such as Sleeping Beauty (Izsvak et al. J. Mol. Biol. 302:93-102 (2000)), or an artificial chromosome. Preferably, vectors such as pACYC177, pACYC184, pCL1920, pECCG117, pUC19, pBR322 and pMW118 can be used, and more preferably pCL_PCJ1 which is pCL1920 vector inserted with CJ1 promoter (KR20060068505) can be used.
In the present invention, the polynucleotide may be operably linked to a recombinant vector. The term “operably linked” refers to the operable linking of a regulatory sequence for nucleotide expression with a nucleotide sequence encoding a target protein for performing its general function, thereby affecting the expression of a coding nucleotide sequence. Operable linking with a recombinant vector can be made by using a gene recombination technique known in the art, and a site-specific DNA cleavage and ligation can be done by using a restriction enzyme and ligase known in the art.
In addition, the recombinant vector may further comprise one or more antibiotic resistance genes selected from the group consisting of ampicillin resistance gene, kanamycin resistance gene, and chloramphenicol acetyl transferase gene.
As used herein, the term “antibiotic resistance gene” refers to a gene having resistance to antibiotics, and the cells comprising this gene survive even in the environment treated with the corresponding antibiotic. Therefore, the antibiotic resistance gene is effectively used as a selection marker for a large-scale production of plasmids in E. coli. In the present invention, as the antibiotic resistance gene is not a factor that significantly affects the expression efficiency which is obtained by an optimal combination of components of the vector which is the key feature of the present invention, any common antibiotic resistance gene can be used as a selection marker without limitation. Specifically, the resistance genes against ampicilin, tetracyclin, kanamycin, chloramphenicol, streptomycin, or neomycin can be used, and preferably spectinomycin resistance gene can be used.
As another aspect, the present invention provides a microorganism transformed with the recombinant vector, for producing O-acetylhomoserine sulfhydrylase.
As used herein, the term “transformation” refers to the introduction of genes into a host cell for the expression of the same. The method for transforming the vector of the present invention into the cells may include any method for introducing the nucleotides into the cells, and it can performed by selecting an appropriate standard technique known in the art. Method such as electroporation, calcium phosphate co-precipitation, retroviral infection, microinjection, DEAE-dextran and cationic liposome can be used, but is not limited thereto.
The transformed gene may be inserted into the chromosome of a host cell and located outside the chromosome, as long as it can be expressed in the host cell. In addition, the gene comprises DNA and RNA as a polynucleotide encoding polypeptide, and any gene that can be introduced and expressed in the host cell can be used without limitation. For example, the gene can be introduced into a host cell in a form of expression cassette which is a polynucleotide construct, comprising all the elements required for self-expression. The expression cassette usually comprises a promoter operably linked to the gene, transcription termination signal, ribosome binding sites, and translation termination signal. The expression cassette may be in a form of self-replicable expression vector. In addition, the gene may be the one introduced into a host cell by itself or in a form of polynucleotide construct and operably linked to the sequences required for the expression in the host cell.
As used herein, the term “microorganism transformed with recombinant vector” refers to the cell transfected with a vector comprising the gene encoding at least one target protein. In the present invention, if the microorganism comprises a wild type or mutant protein capable of producing O-acetylhomoserine sulfhydrylase through transformation of the recombinant vector, any of the prokaryotic and eukaryotic microorganisms can be used. For example, microbial strains belonging to Escherichia sp., Erwinia sp., Serratia sp., Providencia sp., Corynebacteria sp., Pseudomonas sp., Leptospira sp., Salmonellar sp., Brevibacteria sp., Hypomononas sp., Chromobacterium sp., and Norcardia sp. or fungi or yeast may be used. Preferably, microbial strain belonging to Escherichia sp., Corynebacteria sp., and Leptospira sp., and yeast, and more preferably microbial strain of Escherichia sp., and most preferably E. coli can be used.
As another aspect, the present invention provides a method for producing methionine or acetic acid, comprising adding the wild type protein, mutant protein, or microorganism producing the same to the mixture of O-acetylhomoserine and methyl mercaptan to thereby react the resulting mixture.
The O-acetylhomoserine refers to the purified form of O-acetylhomoserine or fermentation broth containing O-acetylhomoserine. Also, the methyl mercaptan refers to all of the following forms, a liquefied sodium methyl mercaptan (CH3S—Na) form, and gaseous or liquefied methyl mercaptan (CH3SH) form, as well as a methyl mercaptan comprising dimethylsulfide (DMS) which is disclosed in Patent Publication WO2010/098629. In one example of the present invention, for L-methionine conversion reaction, 5 to 10% homogenate of microorganisms (of a total reaction volume) comprising the polypeptide was added to the fermentation broth of O-acetylhomoserine, and the reaction was initiated by adding 15% Na-methyl mercaptan to the mixture at a pH of 6 to 8. Then, after 2 hours the fermentation broth was collected and the cells were removed therefrom, which was then analyzed by HPLC to identify methionine production. As shown in
As another aspect, the present invention provides a use of the protein as O-acetylhomoserine sulfhydrylase.
As described above, the protein of the present invention may be a wild type protein having the O-acetylhomoserine sulfhydrylase activity derived from Rhodobacter sphaeroides and a mutant protein thereof, and preferably it may be the protein having the amino acid sequence of SEQ ID Nos. 13 and 15 to 18. The protein of the present invention has high substrate specificity toward O-acetylhomoserine, thereby having the activity of O-acetylhomoserine sulfhydrylase or enhanced activity thereof, and therefore it can be used for producing methionine or acetic acid.
[Mode For Invention]
Hereinafter, the constitution and effect of present invention are described in more detail through providing Examples as below. However, these Examples are merely meant to illustrate the present invention, but in no way to limit, the scope of the present invention.
1-1. O-acetylhomoserine Sulfhydrylase from Hyphomonas Species
Primers were generated by obtaining the gene sequence of O-acetylhomoserine sulfhydrylase from Hyphomonas neptunium which converts O-acetylhomoserine to methionine from KEGG website (www.kegg.com). The chromosome of Hyphomonas neptunium was purchased from ATCC (USA). PCR reaction was performed with 30 cycles of denaturation step at 94° C. for 30 seconds, annealing step at 55° C. for 30 seconds, and extension step at 72° C. for 2 minutes, using the chromosome as a template and the primers of SEQ ID Nos. 1 and 2. HL PCR premix kit (Bioneer, Korea) was used for the PCR reaction.
DNA fragments obtained by the PCR reaction were cleaved by NcoI/HindIII and cloned into pCL-PCJ1 vector digested with the same enzymes. The finally prepared vector was named as pCL-PCJ1-MetZhne and the schematic diagram thereof was shown in
1-2. O-acetylhomoserine Sulfhydrylase from Rhodobacter Species
The metZ gene encoding O-acetylhomoserine sulfhydrylase from Rhodobacter sphaeroides which converts O-acetylhomoserine to methionine was cloned in this experiment.
PCR reaction was performed with 30 cycles of denaturation step at 94° C. for 30 seconds, annealing step at 55° C. for 30 seconds, and extension step at 72° C. for 2 minutes, using the chromosome of Rhodobacter sphaeroides as a template and the primers of SEQ ID Nos. 3 and 4.
DNA fragments obtained from the PCR reaction were cleaved by NcoI/HindIII and cloned into pCL-PCJ1 vector (Korea, CJ) digested with the same enzymes. Cell homogenate was obtained by using the cloned vectors in the same way as described in Example 1-1 and it was used in the enzymatic conversion reaction.
The expression level and enzymatic activity were compared between O-acetylhomoserine sulfhydrylase derived from Hyphomonas species and O-acetylhomoserine sulfhydrylase derived from Rhodobacter species by using each of the cell homogenates obtained by the methods of Examples 1-1 and 1-2.
In general, the amount of protein is quantified by using a protein quantification assay from BIO-Rad, as mentioned in Example 1-1, however, when analyzing the mixture of protein with E. coli proteins such as enzyme homogenate, it is difficult to compare the expression level of certain enzymes using the protein quantification method. Therefore, in this experiment SDS-PAGE was used to compare the expression level of the convertase in the cell homogenate obtained from Examples 1-1 and 1-2. As a result of comparing O-acetylhomoserine sulfhydrylase derived from Hyphomonas species (Metz-hne) and O-acetylhomoserine sulfhydrylase derived from Rhodobacter species (MetZ-rsp) using 10 μl, 5 μl, and 2.5 μl of two cell homogenates, it was observed that MetZ-rsp showed about 4 times higher expression level than MetZ-hne (
In order to determine substrate specificity of two enzymes, O-acylhomoserine was dissolved in 0.1M potassium phosphate buffer (pH 7.5) to a final concentration of 3 mM. In addition, pyridoxal 5′-phosphate (Sigma, USA), which is used as a cofactor, was added to the reaction mixture to a final concentration of 10 μM. Another substrate methyl mercaptan (Japan Tokyo Chemical Industry Ltd.) was added to the reaction mixture to a final concentration of 2 mM. The 1 ml of reaction mixture was put at 37° C., and then 10 μl of each enzyme extract was added to make a final protein concentration of 5 mg/ml. The progress of the reaction was confirmed by measuring the absorbance at 415 nm by collecting 100 μl of the reaction mixture after reaction started and adding it to 900 μl of 4 mg/ml DTNB solution (5,5-dithiobis(2-nitro-benzoic acid), Sigma, USA).
DTNB reacts with —SH group of methyl mercaptan remaining in the reaction mixture and synthesizes a yellow substance. Therefore, the progress of the reaction can be monitored by observing the disappearance of yellow colour in the reaction mixture as the methyl mercaptan in the reaction mixture is converted to methionine. Also, if the difference in DTNB absorbance before and after the reaction (ΔO.D.415) is high, it suggests that the activity of enzyme is strong.
As a result of reaction O-acylhomoserine reaction mixture and enzyme solution, it was observed that both O-acetylhomoserine sulfhydrylase derived from Hyphomonas neptunium and O-acetylhomoserine sulfhydrylase derived from Rhodobacter sphaeroides showed higher substrate specificity toward O-acetylhomoserine than O-succinylhomoserine. The substrate specificity of each enzyme is shown simply as the number of ‘+’ in Table 1. Overall, it was identified that both of the two strains have higher substrate specificity toward O-acetylhomoserine than O-succinylhomoserine.
Hyphomonas Neptunium
Rhodobacter sphaeroides
In order to compare the conversion rates of MetZ-hne and MetZ-rsp enzymes in high concentration of O-acetylhomoserine, methionine conversion experiment was performed at O-acetylhomoserine concentration of 80 g/L. The relative methionine production rates were compared between O-acetylhomoserine sulfhydrylase derived from Hyphomonas neptunium and O-acetylhomoserine sulfhydrylase derived from Rhodobacter sphaeroides from the enzymatic conversion of 80 g/L O-acetylhomoserine in 1 ml tube scale over time. Reaction rates of O-acetylhomoserine sulfhydrylase can be compared by measuring the concentration of methionine produced from the reaction. More specifically, enzymatic conversion reaction was performed at 33° C. by adding 0.01 ml of sodium methyl mercaptan (15%, w/v) which is another substrate required for producing methionine, 0.01 ml of O-acetylhomoserine sulfhydrylase, and 0.1 mM pyridoxal 5′-phosphate the enzyme cofactor to 1 ml of 80 g/L O-acetylhomoserine, and stirring at 800 rpm. Each of the enzyme extracts was added to a final protein concentration of 5 mg/ml. The concentration of methionine and O-acetylhomoserine was analyzed by HPLC. The rate of methionine conversion was calculated as the number of moles of methionine produced from 1 mole of methyl mercaptan added into the reaction.
As shown in Table 2, O-acetylhomoserine sulfhydrylase derived from Rhodobacter sphaeroides showed higher reaction rate during early phase and higher conversion rate than O-acetylhomoserine sulfhydrylase derived from Hyphomonas neptunium even at high concentration of O-acetylhomoserine.
In the two-step method, L-methionine and acetic acid are produced in the enzymatic reaction. However, it is known that a high concentration of L-methionine reduces the enzymatic reaction rate and acetic acid inhibits the enzyme activity through protein alteration.
For the enzymatic conversion of O-acetylhomoserine to L-methionine and acetic acid for industrial purpose, the enzyme should maintain high activity even with the above-described inhibition of enzyme activity. The activities of MetZ-hne and MetZ-rsp in the presence of L-methionine and acetic acid at high concentration were compared. Specifically, in the presence of 0.3M L-methionine (about 45 g/L) and 0.3M acetic acid, the activities were compared using a DTNB method described in Example 2. The 25 μl of 5 mg/ml cell homogenate was used in this reaction. The results showed that the residual activity of MetZ-hne and metZ-rsp were 42% and 50% respectively, and thus it was confirmed that Metz-rsp has a lower degree of enzyme activity inhibition even in the presence of L-methionine and acetic acid at high concentration (Table 3).
In addition, the conversion reactions by two enzymes in the presence of 0.3M L-methionine and 0.3M acetic acid were analyzed, and the results are shown in Table 4.
In the enzymatic conversion process on an industrial scale, the reaction goes on for about 1 to 6 hours at a temperature of 33 to 37° C. In addition to a feedback inhibition by reaction products, the enzyme with low thermal stability has lower enzyme activity as the conversion reaction progresses. Thus, the thermal stability of enzyme is an important factor in industrial applicability and cost-effectiveness. In order to compare the thermal stability of the enzymes, each of the cell homogenates obtained by the methods of Examples 1-1 and 1-2 was heat-treated at 50° C. for 10, 30, 60, 120, and 240 minutes, and then the residual activity of enzymes was compared using a DTNB method of Example 2.
As shown in Table 5, O-acetylhomoserine sulfhydrylase derived from Rhodobacter sphaeroides showed the residual activity of 95% after 240 minute-long heat treatment at 45° C. compared to its activity prior to the heat treatment. On the other hand, MetZ-hne showed the residual activity of 75%, thereby suggesting that MetZ-rsp has a superior thermal stability.
In the present example, for evaluating the conversion activity of O-acetylhomoserine sulfhydrylase (metZ-rsp) identified in a tube scale now in a reactor system, a batch reactor having an optimal volume of 1 L was used. O-acetylhomoserine which is a substrate required for enzymatic conversion reaction was produced by fermenting a microbial strain disclosed in the prior art, and the cells were removed from the cultured fermentation broth using a centrifuge. The 500 mL of about 70 g/L culture medium was used (WO2008/013432). Since methyl mercaptan exists in a gaseous form at room temperature, the experiment was performed by using a sodium methyl mercaptan solution in a liquid form (CH3S—Na, 4.7M, 33%, Arkema France) which was generated by adding methyl mercaptan to caustic soda solution. About 50 mL of sodium methyl mercaptan was used in enzymatic conversion reaction. As enzyme solution, 50 mL of MetZ-rsp cell homogenate produced by the method of Example 1 was added to the reaction along with 0.1 mM pyridoxal 5′-phosphate (Sigma, USA). The enzymatic conversion reaction was performed at a pH of 7.0 and at 33° C. with stirring at 700 rpm. The reaction was carried out for 3 hours while adding sodium methyl mercaptan. Concentrations of O-acetylhomoserine and L-methionine produced over the time were analyzed by HPLC and these results are shown in Table 6.
Overall, it was observed that the enzymatic conversion reaction of O-acetylhomoserine medium to L-methionine using a MetZ-rsp enzyme solution in a 1 L batch reactor was fast and showed high conversion rate (97% mol conversion rate).
In the present example, to evaluate the scale-up enzymatic conversion reaction system of methionine through the conversion activity of O-acetylhomoserine sulfhydrylase (metZ-rsp) identified in the 1 L batch reactor, methionine conversion reaction was performed using a 30 L batch reactor (Korea fermenter, Korea). O-acetylhomoserine which is a substrate required in enzymatic conversion reaction was produced, as in Example 6, by fermenting the microbial strains disclosed in prior art (WO2008/013432), and the microbial strain were removed from the cultured fermentation broth using a centrifuge. Supernatant was diluted by adding water to make the concentration of O-acetylhomoserine 66 g/L, and used in the reaction.
After 23 L of diluted fermentation supernatant was put in the fermenter, 500 ml of metZ-rsp enzyme homogenate generated by the method described in Example 1 was added to the same, and then a cofactor pyridoxal 5′-phosphate (Sigma, USA) was added to a final concentration of 0.1 mM. Subsequently, a pH of the reaction mixture was adjusted to 6.5 by adding ammonia gas and the temperature and stirring were set at 37° C. and at 300 rpm, respectively.
Methyl mercaptan (CH3SH, 99.5%, UK, Intergas) in gaseous form was used, and it was put directly into the reaction mixture while controlling the amount of gas added using a mass flow controller. Since some of methyl mercaptan was evaporated in the reaction mixture and increased the pressure inside the reactor, the speed of supplying methyl mercaptan was adjusted to maintain the pressure to be less than 0.5 bar. About 220 L (470 g) of methyl mercaptan was added to the reaction for a total of 120 minutes while controlling the supplying speed to 3 to 5 L/min for the first 30 minutes of the fast reaction period and then to 1 to 2 L/min for the remaining 90 minutes of the slow reaction period. The total amount of methyl mercaptan added is the same molar amount as O-acetylhomoserine present in the reaction mixture during the enzymatic conversion reaction, all of which was consumed during synthesis of methionine. After completion of the reaction, the residual amount of methyl mercaptan was less than 0.1 g/L.
Since during the reaction, every time 1 mole of methionine is produced 1 mole of acetic acid is produced reducing the pH, a pH of the reaction was maintained to 6.5 by adding ammonia gas to raise the pH whenever it falls to 6.48. Reaction rate can be determined by measuring the slope of pH decrease, and the completion of reaction can be determined when pH decrease is slow.
The reaction was carried out for 6 hours while adding methyl mercaptan to the reaction. Changes in the concentrations of O-acetylhomoserine and L-methionine over time were analyzed by HPLC and the results are shown in
The pH change profile during the reaction is shown in
Overall, it was confirmed that even when gaseous methyl mercaptan was used in the enzymatic conversion reaction of O-acetylhomoserine medium to L-methionine using a metZ-rsp enzyme solution in a 30 L batch reactor, the methionine conversion with 98% molar conversion rate for 6 hours could be achieved.
In the present example, error-prone PCR was performed to induce random mutagenesis in a wild type metZ-rsp, and for this experiment a diversify PCR random mutagenesis kit (CLONTECH, USA) was used. In order to find the optimal conditions for establishing a target mutation rate, error-prone PCR was performed under the following two conditions at various concentrations of MnSO4 and dGTP. The pCL-PCJ1:metZ-rsp cloned in Example 1-2 was used as a DNA template where mutations are to be introduced.
The products of error-prone PCR performed under the conditions of Table 7 were cleaved with NcoI/HindIII, and cloned into pCL-PCJ1 vector which was digested with the same enzymes. The cloned mutant library was transformed into Escherichia coli K12 cells, which were then cultured in a LB medium plate containing 50 μg/L pectinomycin. After culturing, 50 colonies were selected, and then sequencing analysis was performed to determine the mutation rate and check the occurrence of mutation at various locations. Sequencing analysis results demonstrated that the mutation rate was 2.4 kb−1 under Condition 1, and 2.9 kb−1 under Condition 2. Based on these results, it was determined that both of Conditions 1 and 2 could yield a suitable mutation rate for generating a mutant library, and thus screening of valid mutations was performed using the libraries produced under the above conditions.
The resulting cells were cultured in a first 96 deep-well plate, and treated with BugBuster solution in 1:1 ratio (MERCK, USA) to obtain cell homogenate. Then, 50 μl of the cell homogenate was collected and mixed with 50 μl of reaction mixture comprising 300 mM O-acetylhomoserine and 1 mM substrate of L-cysteine. The resulting reaction mixture was reacted for 60 minutes at a room temperature while adding 50 uL of DTNB solution at designated times. The O.D. values were measured at 415 nm after color formation and the results are shown in Table 8.
In the plot of DTNB color level over time, the O.D. values of residual L-cysteine are 1.19 and 0.65 at 5 minutes and 10 minutes after the reaction, respectively. In the actual screening, the mutants with less than 1.0 DTNB color level of residual cysteine after 5 minutes of enzymatic reaction were selected.
Candidate mutants that showed significantly increased activity were selected using the above screening method. Subsequently, nucleotide sequence alignment was performed to screen the valid mutation in the candidate mutants. Then finally the mutants comprising 4 types of mutations such as 13N (SEQ ID NO: 15), F65Y (SEQ ID NO: 16), V104A (SEQ ID NO: 17) and E182G were selected. Finally selected mutations were to be introduced as a candidate mutation, and by introducing each type of candidate mutations individually to a pCL-PCJ1:metZ-rsp standard vector, the increased activity was validated. To generate the vectors introduced with each type of candidate mutations, the metZ-rsp expression vector introduced with each candidate mutation was produced using the primers of SEQ ID Nos. 5 and 6 for I3N mutation, the primers of SEQ ID Nos. 7 and 8 for F65Y mutation, the primers of SEQ ID Nos. 9 and 10 for 104A mutation, and the primers of SEQ ID Nos. 11 and 12 for E182G mutation. Successful introduction of mutation was confirmed by sequencing analysis (Macrogen, Korea). The generated mutant vector was transformed into E. coli K12, and cultured in a LB medium flask at 33° C. and 200 rpm for 15 hours. Then the cultured samples were analyzed to validate each candidate mutation. Results are shown in Table 9.
The flask evaluation after introducing each candidate mutation demonstrated that I3N (SEQ ID No. 15), F65Y (SEQ ID No. 16), and V104A (SEQ ID No. 17) are the valid mutation showing increased activity compared to the existing control group of metZ-rsp. On the other hand, E182G mutation was determined to be invalid for having increased activity, and thus it was excluded for the subsequent experiment.
All of the three types of valid mutations including I3N, F65Y and V104A that were confirmed to have increased activity were introduced into the vector pCL-PCJ1:metZ-rsp vector (named as pCL-PCJ1:metZ-rspM3) to generate a vector with even more enhanced activity. Three types of mutations were introduced one by one into the vector using the above-listed primers. The prepared expression vector with three types of mutations was transformed into E. coli K12 and cultured in a flask. Then the cell culture was analyzed to evaluate the activity of the expression vector and the results are shown in Table 10.
As shown in Table 10, it was confirmed that the pCL-PCJ1:metZ-rsp M3 with three types of valid mutations introduced have 1.75 times increased activity than the pCL-PCJ1:metZ-rsp.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10-2010-0131954 | Dec 2010 | KR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/KR2011/009965 | 12/21/2011 | WO | 00 | 6/21/2013 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2012/087038 | 6/28/2012 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 7611873 | Usuda et al. | Nov 2009 | B1 |
| 7662943 | Park et al. | Feb 2010 | B2 |
| 7851180 | Shin et al. | Dec 2010 | B2 |
| 8426171 | Kim et al. | Apr 2013 | B2 |
| 20100184164 | Kim et al. | Jul 2010 | A1 |
| 20120123158 | Kim et al. | May 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 2009-544309 | Dec 2009 | JP |
| 2004108894 | Dec 2004 | WO |
| WO 2008013432 | Jan 2008 | WO |
| Entry |
|---|
| GenBank Accession No. YP—002524520.1, available 2009. |
| GenBank Accession No. EEW25407.1, published 2009. |
| GenBank Accession No. EBA03892.1, published 2007. |
| GenBank Accession No. YP—509796.1, available 2007. |
| Chen et al., “Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo,” Gene Therapy 11:856-864, 2004. |
| Ehrhardt et al., “Optimization of Cis-Acting Elements for Gene Expression from Nonviral Vectors In Vivo,” Human Gene Therapy 14:215-225, Feb. 10, 2003. |
| Izsvák et al., “Sleeping Beauty, a Wide Host-range Transposon Vector for Genetic Transformation in Vertebrates,” J. Mol. Biol. 302:93-102, 2000. |
| Yew et al., “CpG-Depleted Plasmid DNA Vectors with Enhanced Safety and Long-Term Gene Expression in Vivo,” Molecular Therapy 5(6):731-738, Jun. 2002. |
| NCBI, GenBank accession No. CP000143.1, Oct. 7, 2005. |
| Yamagata “Roles of O -acetyl-L -homoserine sulfhydrylases in micro-organisms,” Biochimie 71:1125-1143 (1989). |
| UniProtKB Entry Q3J5D4—Comparing version 1 to 55, XP-002728470, http://www.uniprot.org/uniprot/Q3J5D4?version=1&version=55 (1 page) (Aug. 13, 2014). |
| Number | Date | Country | |
|---|---|---|---|
| 20130273614 A1 | Oct 2013 | US |
